Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ariana® Pharma and CTCLS Sign Japanese Distribution Agreement

Published: Thursday, November 01, 2012
Last Updated: Thursday, November 01, 2012
Bookmark and Share
Ariana continues global expansion from US to Japan with KEM® data analytics software and services technology.

Ariana Pharma has announced the signing of an exclusive Japanese distribution agreement with CTC Laboratory Systems Corporation (CTCLS), the Japanese supplier of services for R&D solutions.

CTCLS will distribute Ariana’s KEM® data analytics software and services technology to Japanese markets. Ariana selected CTCLS as its Japanese distribution partner because of the company’s dominant presence in Japan.

CTCLS is a leading R&D service provider, offering total solutions to major industries and specializing in the pharmaceutical sector.

Ariana’s KEM®, or Knowledge Extraction and Management, is a novel, association rules-based (non-statistical) data-analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect.

In the life science industry, KEM saves sponsors both time and money by optimizing clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints.

“In the first half of 2012, we expanded west from Europe to launch our US office, and now we’re progressing into the Far East with the CTCLS distribution agreement,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma.

Dr. Afshar continued, “This deal with CTCLS will provide an excellent entry into Asia and the world's third largest biotechnology market. We expect the ongoing growth of Japanese companies in medicine development, diagnostics and biomarker studies will further increase demand for Ariana’s KEM® software.”

“After having invested resources in acquiring equipment and establishing processes to generate data, our clients are now focusing on technologies that extract valuable information and exploit data to the fullest extent,” said Hideki Negishi, president and CEO of CTCLS.

Negishi continued, “CTCLS is selecting leading technologies in pharmaceutical and manufacturing areas to deliver to the Japanese markets. We are confident that the application of KEM will accelerate developments in these industries.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ariana® Pharma Enters Viral Hepatitis Partnership with Bio-Rad, INSERM and Beaujon Hospital
Hepachronix project will pool expertise to develop and market an in vitro diagnostic kit for chronic, viral hepatitis.
Monday, November 22, 2010
Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos